(Q39557421)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21499301%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

title

Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21499301%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21499301%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

J Tanizaki

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21499301%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

I Okamoto

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21499301%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

W Okamoto

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21499301%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

K Nishio

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21499301%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

K Nakagawa

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21499301%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

language of work or name

English

0 references

publication date

18 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21499301%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21499301%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21499301%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

4097-4106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21499301%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21499301%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/onc.2011.111

28 January 2020

exact match

0 references

cites work

Validating survivin as a cancer therapeutic target

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Rare cancer-specific mutations in PIK3CA show gain of function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Studies of the HER-2/neu proto-oncogene in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

The survivin-like C. elegans BIR-1 protein acts with the Aurora-like kinase AIR-2 to affect chromosomes and the spindle midzone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.111

31 March 2020

Identifiers

DOI

10.1038/ONC.2011.111

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21499301%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference